Related references
Note: Only part of the references are listed.Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients
Lucia Perez-Lamas et al.
BLOOD (2021)
A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
Fatima Khadadah et al.
BLOOD (2021)
Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations
David Andorsky et al.
BLOOD (2021)
The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation
Anna G. Turkina et al.
BLOOD (2021)
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Valentin Garcia-Gutierrez et al.
BLOOD CANCER JOURNAL (2021)
Third-line therapy for chronic myeloid leukemia: current status and future directions
Jorge Cortes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
Jorge Cortes et al.
BLOOD (2021)
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Delphine Rea et al.
BLOOD (2021)
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Massimo Breccia et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment
Matthias Hoch et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Mahran Shoukier et al.
CURRENT ONCOLOGY REPORTS (2021)
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
Young Rok Do et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
Andreas Hochhaus et al.
LEUKEMIA (2020)
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Andreas Hochhaus et al.
LEUKEMIA (2020)
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
Paul W. Manley et al.
LEUKEMIA RESEARCH (2020)
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Valentin Garcia-Gutierrez et al.
FRONTIERS IN ONCOLOGY (2019)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide et al.
CANCER CELL (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers
Hans D. Menssen et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 41, 2017)
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2018)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
David J. Dorer et al.
LEUKEMIA RESEARCH (2016)
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
Sung-Hyun Kim et al.
HAEMATOLOGICA (2014)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?
Elias Jabbour et al.
SEMINARS IN HEMATOLOGY (2010)
Tyrosine kinase inhibitors in cancer therapy
S Madhusudan et al.
CLINICAL BIOCHEMISTRY (2004)
Share Paper
